Published in Hepatitis Weekly, March 15th, 2004
According to a study from Italy, "in this pilot study, we evaluated the efficacy of interferon-alpha (IFN) plus thymosin-alpha 1 (TA1) to that of IFN alone in naive patients with chronic hepatitis C. Twenty-two patients were randomized to receive interferon-alpha(2b) (3 million units three times a week) plus thymosin-alpha l (900 microgram/m2 body surface area) and 19 received interferon-alpha(2b) alone at the same dose. Patients were treated for 6 months and followed up for another 6 months."
"Biochemical (alanine aminotransferase values) and virological...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly